The Gastrointestinal Tolerability of the LOX/COX Inhibitor, Licofelone, is Similar to Placebo and Superior to Naproxen Therapy in Healthy Volunteers: Results from a Randomized, Controlled Trial

American Journal of Gastroenterology

Volumn 99, Issue 4, 2004, Pages 611-618

  Bias, Peter ^a   Buchner, Anton ^b   Klesser, Bernhard ^b   Laufer, Stefan ^b  

^a TEVA PHARMACEUTICALS   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; LICOFELONE; LIPOXYGENASE INHIBITOR; NAPROXEN; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DUODENOSCOPY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROSCOPY; HUMAN; INCIDENCE; MALE; NORMAL HUMAN; OSTEOARTHRITIS; PARAMETER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECORDING; SCORING SYSTEM; SIDE EFFECT; STOMACH EROSION; STOMACH MUCOSA; TABLET FORMULATION; ULCER;

ACETIC ACIDS; ADULT; ARACHIDONATE 5-LIPOXYGENASE; CYCLOOXYGENASE INHIBITORS; DUODENOSCOPY; DUODENUM; FEMALE; GASTRIC MUCOSA; GASTROSCOPY; HUMANS; INCIDENCE; INTESTINAL MUCOSA; MALE; NAPROXEN; PEPTIC ULCER; PYRROLES;

EID: 2342496237     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.04133.x     Document Type: Article

References (38)

1. Brooks P, Emery P, Evans JF, et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology (Oxford) 1999;38:779-88.
2. Komers R, Anderson S, Epstein M. Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. Am J Kidney Dis 2001;38:1145-57.
3. Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum 2002;32:33-42.
4. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal andinflammatory drugs. N Engl J Med 1999;340:1888-99.
5. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999; 26(Suppl 56):18-24.
6. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
7. Cheng HF, Harris RC. Does cyclooxygenase-2 affect blood pressure? Curr Hypertens Rep 2003;5:87-92.
8. FitzGerald GA. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: Clinical considerations. Am J Cardiol 2002;89:26D-32D.
9. Galli G, Panzetta G. Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects? J Nephrol 2002;15:480-8.
10. Martel-Pelletier J, Lajeunesse D, Reboul P, et al. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2003;62:501-9.
11. Simon LS, Smolen JS, Abramson SB, et al. Controversies in COX-2 selective inhibition. J Rheumatol 2002;29:1501-10.
12. Mukherjee D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol 2002;63:817-21.
13. Laufer S. Discovery and development of ML3000. Inflammopharmacology 2001;9:101-12.
14. Skelly MM, Hawkey CJ. COX-LOX inhibition: Current evidence for an emerging new therapy. Int J Clin Prac 2003; 57:301-4.
15. Bertolini A, Ottani A, Sandrini M. Dual acting anti-inflammatory drugs: A reappraisal. Pharmacol Res 2001; 44:437-50.
16. Celotti F, Laufer S. Anti-inflammatory drugs: New multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol Res 2001;43:429-36.
17. Sahap Atik O. Leukotriene B4 and prostaglandin E2-like activity in synovial fluid in osteoarthritis. Prostaglandins Leukot Essent Fatty Acids 1990;39:253-4.
18. Laufer SA, Augustin J, Dannhardt G, et al. (6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J Med Chem 1994;37:1894-7.
19. Laufer S, Tries S, Augustin J, et al. Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. Arzneimittelforschung 1994;44:629-36.
20. Laufer S, Tries S, Augustin J, et al. Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl] -acetic acid. Arzneimittelforschung 1995;45:27-32.
21. Laufer S, Tries S, Augustin J, et al. Gastrointestinal tolerance of [2,2-dimethyl-6-(4-chlorophenyl-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl] -acetic acid in the rat. Arzneimittelforschung 1994;44:1329-33.
22. Lanza FL. Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal anti-inflammatory agents. Am J Med 1984;77:19-24.
23. Laine L, Sloane R, Ferretti M, et al. A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc 1995;42:428-33.
24. Lanza FL. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs. Scand J Gastroenterol Suppl 1989;163:24-31.
25. Patoia L, Santucci L, Fumo P, et al. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br J Rheumatol 1996;35(Suppl 1):61-7.
26. Roth SH, Bennett RE, Caldron PH. Endoscopic evaluation of the long term effects of diclofenac sodium and naproxen in elderly patients with arthritis. Clin Drug Invest 1995;9:171-9.
27. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993;153:2565-71.
28. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996;334:1435-9.
29. Cheatum DE, Arvanitakis C, Gumpel M, et al. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. Clin Ther 1999;21:992-1003.
30. Reginster J, Bias P, Buchner A. First clinical results of licofelone (ML3000), an inhibitor of COX-1, COX-2 and 5 LOX, for the treatment of osteoarthritis. Ann Rheum Dis 2002;61 (Suppl. 1):116 (abstract THU0189).
31. Blanco F, Buchner A, Bias P, et al. Licofelone, an inhibitor of COX-1, COX-2 and 5-LOX, is as effective as naproxen and shows improved safety during 12 months of treatment in patients with osteoarthritis of the knee (abstract FRI0217). Ann Rheum Dis 2003;62(Suppl 1):262.
32. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591-602.
33. Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96:1019-27.
34. Sikes DH, Agrawal NM, Zhao WW, et al. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002;14:1101-11.
35. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
36. Hunt RH, Harper S, Callegari P, et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003;17:201-10.
37. Rordorf C, Kellett N, Mair S, et al. Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: A pilot endoscopic study in healthy male subjects. Aliment Pharmacol Ther 2003;18:533-41.
38. Pavelka K, Bias P, Buchner A, et al. Licofelone, an inhibitor of COX-1, COX-2 and 5-LOX, is as effective as celecoxib and shows improved tolerability during 12 weeks of treatment in patients with OA of the knee (abstract FRI0215). Ann Rheum Dis 2003;62(Suppl 1): 261.